David A. Siegel Oramed Pharmaceuticals Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ORMP
# of Institutions
63Shares Held
7.4MCall Options Held
4KPut Options Held
2.1K-
Bml Capital Management, LLC Zionsville, IN2.19MShares$4.74 Million3.14% of portfolio
-
Murchinson Ltd. Toronto, A61.71MShares$3.71 Million1.22% of portfolio
-
Boothbay Fund Management, LLC New York, NY828KShares$1.8 Million0.06% of portfolio
-
Morgan Jess S & CO Inc366KShares$795,0902.07% of portfolio
-
Rathbones Group PLC Liverpool, X0290KShares$628,8720.0% of portfolio
About ORAMED PHARMACEUTICALS INC.
- Ticker ORMP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,100
- Market Cap $84.3M
- Description
- Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...